Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
10.75
+0.03 (0.28%)
At close: Nov 20, 2024, 4:00 PM
10.90
+0.15 (1.40%)
Pre-market: Nov 21, 2024, 7:30 AM EST
Avadel Pharmaceuticals Employees
Avadel Pharmaceuticals had 154 employees as of December 31, 2023. The number of employees increased by 113 or 275.61% compared to the previous year.
Employees
154
Change (1Y)
113
Growth (1Y)
275.61%
Revenue / Employee
$897,143
Profits / Employee
-$471,266
Market Cap
1.04B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Brookdale Senior Living | 36,000 |
The Pennant Group | 5,791 |
OPKO Health | 3,930 |
Phreesia | 1,438 |
Weave Communications | 844 |
ANI Pharmaceuticals | 642 |
Zymeworks | 278 |
Cogent Biosciences | 164 |
AVDL News
- 8 days ago - Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 8 days ago - Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation - GlobeNewsWire
- 5 weeks ago - US FDA expands approval for Avadel's sleep disorder drug - Reuters
- 5 weeks ago - Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy - GlobeNewsWire
- 2 months ago - Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On - Seeking Alpha
- 2 months ago - Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII) - GlobeNewsWire
- 3 months ago - Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire